B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $191
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Buy rating on Ascendis Pharma and raised the price target from $175 to $191, indicating confidence in the company's future performance.
September 23, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has maintained a Buy rating on Ascendis Pharma and increased the price target from $175 to $191, suggesting a positive outlook for the company's stock.
The increase in the price target from $175 to $191 by B of A Securities reflects a positive sentiment towards Ascendis Pharma's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100